Reduced Intensity Allogeneic Stem Cell Transplant with Anti-Thymocyte globulin and Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia.
Eur J Haematol. 2019 Aug 26;:
Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment.
Eur J Haematol. 2019 Aug 16;:
Epstein-Barr virus associated post-transplant lymphoproliferative disorder mimicking acute graft versus host disease.
Eur J Haematol. 2019 Aug 07;:
Combination of the Centre for International Blood and Marrow Transplant Registry Risk Score and the Global Severity Score Enhances Prognostic Risk Stratification in Patients Receiving Frontline Therapy for Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant. 2019 Jun 04;:
Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants.
Eur J Haematol. 2019 Mar 29;:
Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
Eur J Haematol. 2019 Apr;102(4):368-374
Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.
Biol Blood Marrow Transplant. 2019 Jan 14;:
Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2018 02;24(2):366-372
Reduced Intensity Conditioning and Dual T-Lymphocyte Suppression with Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis In Haploidentical Stem Cell Transplants For Hematological Malignancies.
Biol Blood Marrow Transplant. 2018 Jul 12;: